Kynurenic Acid in Schizophrenia: A Systematic Review and Meta-analysis

Schizophrenia Bulletin

Volumn 43, Issue 4, 2017, Pages 764-777

  Plitman, Eric ^a,b   Iwata, Yusuke ^a   Caravaggio, Fernando ^a   Nakajima, Shinichiro ^a,c,d   Chung, Jun Ku ^a,b   Gerretsen, Philip ^a,c   Kim, Julia ^a,b   Takeuchi, Hiroyoshi ^a,c,d   Chakravarty, M Mallar ^e,f   Remington, Gary ^a,b,c   Graff Guerrero, Ariel ^a,b,c  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d KEIO UNIVERSITY   (Japan)

^e DOUGLAS MENTAL HEALTH UNIVERSITY INSTITUTE   (Canada)

^f MCGILL UNIVERSITY   (Canada)

Author keywords

kynurenine; neuroinflammation; psychosis; tryptophan

Indexed keywords

KYNURENIC ACID; KYNURENINE; NEUROLEPTIC AGENT;

AMINO ACID BLOOD LEVEL; BRAIN TISSUE; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID LEVEL; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; REVIEW; SCHIZOPHRENIA; SYSTEMATIC REVIEW; ADULT; BLOOD; FEMALE; MALE; METABOLISM;

ADULT; FEMALE; HUMANS; KYNURENIC ACID; MALE; SCHIZOPHRENIA;

EID: 85021819812     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbw221     Document Type: Review

References (144)

1. Howes O, McCutcheon R, Stone J. Glutamate and dopamine in schizophrenia: An update for the 21st century. J Psychopharmacol. 2015;29:97-115.
2. Poels EM, Kegeles LS, Kantrowitz JT, et al. Imaging glutamate in schizophrenia: review of findings and implications for drug discovery. Mol Psychiatry. 2014;19:20-29.
3. Hietala J, Syvalahti E, Vuorio K, et al. Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. Lancet. 1995;346:1130-1131.
4. Demjaha A, Murray RM, McGuire PK, Kapur S, Howes OD. Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. Am J Psychiatry. 2012;169:1203-1210.
5. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III-the final common pathway. Schizophr Bull. 2009;35:549-562.
6. Laruelle M, Abi-Dargham A, Van Dyck CH, et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci U S A. 1996;93:9235.
7. Seeman P, Lee T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science. 1975;188:1217-1219.
8. Fusar-Poli P, Papanastasiou E, Stahl D, et al. Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials. Schizophr Bull. 2015;41:892-899.
9. Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA. Pharmacological treatment of schizophrenia: A critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry. 2012;17:1206-1227.
10. Lindenmayer JP. Treatment refractory schizophrenia. Psychiatr Q. 2000;71:373-384.
11. Suzuki T, Remington G, Mulsant BH, et al. Treatment resistant schizophrenia and response to antipsychotics: A review. Schizophr Res. 2011;133:54-62.
12. Adler CM, Malhotra AK, Elman I, et al. Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. Am J Psychiatry. 1999;156:1646-1649.
13. Krystal JH, Perry EB Jr, Gueorguieva R, et al. Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. Arch Gen Psychiatry. 2005;62:985-994.
14. Krystal JH, Bennett A, Abi-Saab D, et al. Dissociation of ketamine effects on rule acquisition and rule implementation: possible relevance to NMDA receptor contributions to executive cognitive functions. Biol Psychiatry. 2000;47:137-143.
15. Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 1994;51:199-214.
16. Lahti AC, Weiler MA, Tamara Michaelidis BA, Parwani A, Tamminga CA. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology. 2001;25:455-467.
17. Malhotra AK, Pinals DA, Weingartner H, et al. NMDA receptor function and human cognition: The effects of ketamine in healthy volunteers. Neuropsychopharmacology. 1996;14:301-307.
18. Lahti AC, Holcomb HH, Medoff DR, Tamminga CA. Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport. 1995;6:869-872.
19. Lahti AC, Koffel B, LaPorte D, Tamminga CA. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology. 1995;13:9-19.
20. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry. 1995;52:998-1007.
21. Rowland LM, Bustillo JR, Mullins PG, et al. Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: A 4-T proton MRS study. Am J Psychiatry. 2005;162:394-396.
22. Stone JM, Dietrich C, Edden R, et al. Ketamine effects on brain GABA and glutamate levels with 1H-MRS: relationship to ketamine-induced psychopathology. Mol Psychiatry. 2012;17:664-665.
23. Bartha R, Williamson PC, Drost DJ, et al. Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. Arch Gen Psychiatry. 1997;54:959-965.
24. de la Fuente-Sandoval C, Leon-Ortiz P, Favila R, et al. Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis. Neuropsychopharmacology. 2011;36:1781-1791.
25. Kegeles LS, Mao X, Stanford AD, et al. Elevated prefrontal cortex-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy. Arch Gen Psychiatry. 2012;69:449-459.
26. Kraguljac NV, White DM, Reid MA, Lahti AC. Increased hippocampal glutamate and volumetric deficits in unmedicated patients with schizophrenia. JAMA Psychiatry. 2013;70:1294-1302.
27. Plitman E, de la Fuente-Sandoval C, Reyes-Madrigal F, et al. Elevated myo-inositol, choline, and glutamate levels in the associative striatum of antipsychotic-naive patients with firstepisode psychosis: A proton magnetic resonance spectroscopy study with implications for glial dysfunction. Schizophr Bull. 2016;42:415-424.
28. Theberge J, Bartha R, Drost DJ, et al. Glutamate and glutamine measured with 4. 0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. Am J Psychiatry. 2002;159:1944-1946.
29. Leklem JE. Quantitative aspects of tryptophan metabolism in humans and other species: A review. Am J Clin Nutr. 1971;24:659-672.
30. Dounay AB, Tuttle JB, Verhoest PR. Challenges and opportunities in the discovery of new therapeutics targeting the kynurenine pathway. J Med Chem. 2015;58:8762-8782.
31. Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ. Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci. 2012;13:465-477.
32. Vecsei L, Szalardy L, Fulop F, Toldi J. Kynurenines in the CNS: recent advances and new questions. Nat Rev Drug Discov. 2013;12:64-82.
33. Fukui S, Schwarcz R, Rapoport SI, Takada Y, Smith QR. Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J Neurochem. 1991;56:2007-2017.
34. Gal EM, Sherman AD. L-kynurenine: its synthesis and possible regulatory function in brain. Neurochem Res. 1980;5:223-239.
35. Guillemin GJ, Kerr SJ, Smythe GA, et al. Kynurenine pathway metabolism in human astrocytes: A paradox for neuronal protection. J Neurochem. 2001;78:842-853.
36. Guidetti P, Amori L, Sapko MT, Okuno E, Schwarcz R. Mitochondrial aspartate aminotransferase: A third kynurenate-producing enzyme in the mammalian brain. J Neurochem. 2007;102:103-111.
37. Perkins MN, Stone TW. An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res. 1982;247:184-187.
38. Birch PJ, Grossman CJ, Hayes AG. Kynurenic acid antagonises responses to NMDA via an action at the strychnineinsensitive glycine receptor. Eur J Pharmacol. 1988;154:85-87.
39. Kessler M, Terramani T, Lynch G, Baudry M. A glycine site associated with N-methyl-D-aspartic acid receptors: characterization and identification of a new class of antagonists. J Neurochem. 1989;52:1319-1328.
40. Hilmas C, Pereira EF, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque EX. The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases nonalpha7 nicotinic receptor expression: physiopathological implications. J Neurosci. 2001;21:7463-7473.
41. Pocivavsek A, Notarangelo FM, Wu H-Q, Bruno JP, Schwarcz R. Chapter 25-Astrocytes as pharmacological targets in the treatment of schizophrenia: focus on kynurenic acid. In: Mikhail VP, John LW, eds. Handbook of Behavioral Neuroscience. Vol 23. San Diego, CA: Elsevier; 2016:423-443.
42. Wang J, Simonavicius N, Wu X, et al. Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J Biol Chem. 2006;281:22021-22028.
43. DiNatale BC, Murray IA, Schroeder JC, et al. Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling. Toxicol Sci. 2010;115:89-97.
44. Lugo-Huitron R, Blanco-Ayala T, Ugalde-Muniz P, et al. On the antioxidant properties of kynurenic acid: free radical scavenging activity and inhibition of oxidative stress. Neurotoxicol Teratol. 2011;33:538-547.
45. Foster AC, Vezzani A, French ED, Schwarcz R. Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid. Neurosci Lett. 1984;48:273-278.
46. Erhardt S, Schwieler L, Nilsson L, Linderholm K, Engberg G. The kynurenic acid hypothesis of schizophrenia. Physiol Behav. 2007;92:203-209.
47. Myint AM. Kynurenines: from the perspective of major psychiatric disorders. FEBS J. 2012;279:1375-1385.
48. Wonodi I, Schwarcz R. Cortical kynurenine pathway metabolism: A novel target for cognitive enhancement in Schizophrenia. Schizophr Bull. 2010;36:211-218.
49. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. J Clin Epidemiol. 2009;62:1006-1012.
50. Erhardt S, Olsson SK, Engberg G. Pharmacological manipulation of kynurenic acid: potential in the treatment of psychiatric disorders. CNS Drugs. 2009;23:91-101.
51. Muller N, Myint AM, Schwarz MJ. Kynurenine pathway in schizophrenia: pathophysiological and therapeutic aspects. Curr Pharm Des. 2011;17:130-136.
52. Schwarcz R. Kynurenines and glutamate: multiple links and therapeutic implications. Adv Pharmacol. 2016;76:13-37.
53. Stone TW, Darlington LG. The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders. Br J Pharmacol. 2013;169:1211-1227.
54. Stone TW, Stoy N, Darlington LG. An expanding range of targets for kynurenine metabolites of tryptophan. Trends Pharmacol Sci. 2013;34:136-143.
55. Iwata Y, Nakajima S, Suzuki T, et al. Effects of glutamate positive modulators on cognitive deficits in schizophrenia: A systematic review and meta-analysis of double-blind randomized controlled trials. Mol Psychiatry. 2015;20:1151-1160.
56. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
57. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-634.
58. Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in metaanalysis. Biometrics. 2000;56:455-463.
59. Kim SY, Park JE, Lee YJ, et al. Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity. J Clin Epidemiol. 2013;66:408-414.
60. Barry S, Clarke G, Scully P, Dinan TG. Kynurenine pathway in psychosis: evidence of increased tryptophan degradation. J Psychopharmacol. 2009;23:287-294.
61. Chiappelli J, Pocivavsek A, Nugent KL, et al. Stress-induced increase in kynurenic acid as a potential biomarker for patients with schizophrenia and distress intolerance. JAMA Psychiatry. 2014;71:761-768.
62. Fazio F, Lionetto L, Curto M, et al. Xanthurenic acid activates mGlu2/3 metabotropic glutamate receptors and is a potential trait marker for schizophrenia. Sci Rep. 2015;5:17799.
63. Fukushima T, Iizuka H, Yokota A, et al. Quantitative analyses of schizophrenia-associated metabolites in serum: serum D-lactate levels are negatively correlated with gamma-glutamylcysteine in medicated schizophrenia patients. PLoS One. 2014;9:e101652.
64. Kegel ME, Bhat M, Skogh E, et al. Imbalanced kynurenine pathway in schizophrenia. Int J Tryptophan Res. 2014;7:15-22.
65. Linderholm KR, Skogh E, Olsson SK, et al. Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophr Bull. 2012;38:426-432.
66. Miller CL, Llenos IC, Dulay JR, Weis S. Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Res. 2006;1073-1074:25-37.
67. Myint AM, Schwarz MJ, Verkerk R, et al. Reversal of imbalance between kynurenic acid and 3-hydroxykynurenine by antipsychotics in medication-naive and medication-free schizophrenic patients. Brain Behav Immun. 2011;25:1576-1581.
68. Nilsson LK, Linderholm KR, Engberg G, et al. Elevated levels of kynurenic acid in the cerebrospinal fluid of Male patients with schizophrenia. Schizophr Res. 2005;80:315-322.
69. Ravikumar A, Deepadevi KV, Arun P, Manojkumar V, Kurup PA. Tryptophan and tyrosine catabolic pattern in neuropsychiatric disorders. Neurol India. 2000;48:231-238.
70. Sathyasaikumar KV, Stachowski EK, Wonodi I, et al. Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia. Schizophr Bull. 2011;37:1147-1156.
71. Schwarcz R, Rassoulpour A, Wu HQ, Medoff D, Tamminga CA, Roberts RC. Increased cortical kynurenate content in schizophrenia. Biol Psychiatry. 2001;50:521-530.
72. Schwieler L, Larsson MK, Skogh E, et al. Increased levels of IL-6 in the cerebrospinal fluid of patients with chronic schizophrenia-significance for activation of the kynurenine pathway. J Psychiatry Neurosci. 2015;40:126-133.
73. Erhardt S, Blennow K, Nordin C, Skogh E, Lindstrom LH, Engberg G. Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci Lett. 2001;313:96-98.
74. Muller N, Schwarz M. Schizophrenia as an inflammationmediated dysbalance of glutamatergic neurotransmission. Neurotox Res. 2006;10:131-148.
75. Ceresoli-Borroni G, Rassoulpour A, Wu HQ, Guidetti P, Schwarcz R. Chronic neuroleptic treatment reduces endogenous kynurenic acid levels in rat brain. J Neural Transm (Vienna). 2006;113:1355-1365.
76. Nilsson LK, Nordin C, Jonsson EG, Engberg G, Linderholm KR, Erhardt S. Cerebrospinal fluid kynurenic acid in Male and female controls-correlation with monoamine metabolites and influences of confounding factors. J Psychiatr Res. 2007;41:144-151.
77. Kirkpatrick B, Miller BJ. Inflammation and schizophrenia. Schizophr Bull. 2013;39:1174-1179.
78. Tourjman V, Kouassi E, Koue ME, et al. Antipsychotics' effects on blood levels of cytokines in schizophrenia: A metaanalysis. Schizophr Res. 2013;151:43-47.
79. Upthegrove R, Manzanares-Teson N, Barnes NM. Cytokine function in medication-naive first episode psychosis: A systematic review and meta-analysis. Schizophr Res. 2014;155:101-108.
80. Muller N, Weidinger E, Leitner B, Schwarz MJ. The role of inflammation in schizophrenia. Front Neurosci. 2015;9:372.
81. Steiner J, Bogerts B, Sarnyai Z, et al. Bridging the gap between the immune and glutamate hypotheses of schizophrenia and major depression: potential role of glial NMDA receptor modulators and impaired blood-brain barrier integrity. World J Biol Psychiatry. 2012;13:482-492.
82. Miller CL, Llenos IC, Dulay JR, Barillo MM, Yolken RH, Weis S. Expression of the kynurenine pathway enzyme tryptophan 2, 3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia. Neurobiol Dis. 2004;15:618-629.
83. Wonodi I, Stine OC, Sathyasaikumar KV, et al. Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and geneticassociation with schizophrenia endophenotypes. Arch Gen Psychiatry. 2011;68:665-674.
84. Holtze M, Saetre P, Engberg G, et al. Kynurenine 3-monooxygenase polymorphisms: relevance for kynurenic acid synthesis in patients with schizophrenia and healthy controls. J Psychiatry Neurosci. 2012;37:53-57.
85. Lavebratt C, Olsson S, Backlund L, et al. The KMO allele encoding Arg452 is associated with psychotic features in bipolar disorder type 1, and with increased CSF KYNA level and reduced KMO expression. Mol Psychiatry. 2014;19:334-341.
86. Giorgini F, Huang SY, Sathyasaikumar KV, et al. Targeted deletion of kynurenine 3-monooxygenase in mice: A new tool for studying kynurenine pathway metabolism in periphery and brain. J Biol Chem. 2013;288:36554-36566.
87. Rassoulpour A, Wu HQ, Ferre S, Schwarcz R. Nanomolar concentrations of kynurenic acid reduce extracellular dopamine levels in the striatum. J Neurochem. 2005;93:762-765.
88. Rover S, Cesura AM, Huguenin P, Kettler R, Szente A. Synthesis and biochemical evaluation of N-(4-phenylthiazol-2-yl)benzenesulfonamides as high-affinity inhibitors of kynurenine 3-hydroxylase. J Med Chem. 1997;40:4378-4385.
89. Speciale C, Wu HQ, Cini M, Marconi M, Varasi M, Schwarcz R. (R, S)-3, 4-dichlorobenzoylalanine (FCE 28833A) causes a large and persistent increase in brain kynurenic acid levels in rats. Eur J Pharmacol. 1996;315:263-267.
90. Rothermundt M, Ahn JN, Jorgens S. S100B in schizophrenia: An update. Gen Physiol Biophys. 2009;28 Spec No Focus:F76-F81.
91. Wonodi I, McMahon RP, Krishna N, et al. Influence of kynurenine 3-monooxygenase (KMO) gene polymorphism on cognitive function in schizophrenia. Schizophr Res. 2014;160:80-87.
92. Erhardt S, Schwieler L, Emanuelsson C, Geyer M. Endogenous kynurenic acid disrupts prepulse inhibition. Biol Psychiatry. 2004;56:255-260.
93. Nilsson LK, Linderholm KR, Erhardt S. Subchronic treatment with kynurenine and probenecid: effects on prepulse inhibition and firing of midbrain dopamine neurons. J Neural Transm (Vienna). 2006;113:557-571.
94. Shepard PD, Joy B, Clerkin L, Schwarcz R. Micromolar brain levels of kynurenic acid are associated with a disruption of auditory sensory gating in the rat. Neuropsychopharmacology. 2003;28:1454-1462.
95. Chess AC, Bucci DJ. Increased concentration of cerebral kynurenic acid alters stimulus processing and conditioned responding. Behav Brain Res. 2006;170:326-332.
96. Chess AC, Simoni MK, Alling TE, Bucci DJ. Elevations of endogenous kynurenic acid produce spatial working memory deficits. Schizophr Bull. 2007;33:797-804.
97. Chess AC, Landers AM, Bucci DJ. L-kynurenine treatment alters contextual fear conditioning and context discrimination but not cue-specific fear conditioning. Behav Brain Res. 2009;201:325-331.
98. Pocivavsek A, Thomas MA, Elmer GI, Bruno JP, Schwarcz R. Continuous kynurenine administration during the prenatal period, but not during adolescence, causes learning and memory deficits in adult rats. Psychopharmacology (Berl). 2014;231:2799-2809.
99. Pocivavsek A, Wu HQ, Elmer GI, Bruno JP, Schwarcz R. Pre-and postnatal exposure to kynurenine causes cognitive deficits in adulthood. Eur J Neurosci. 2012;35:1605-1612.
100. Pocivavsek A, Wu HQ, Potter MC, Elmer GI, Pellicciari R, Schwarcz R. Fluctuations in endogenous kynurenic acid control hippocampal glutamate and memory. Neuropsychopharmacology. 2011;36:2357-2367.
101. Alexander KS, Pocivavsek A, Wu HQ, Pershing ML, Schwarcz R, Bruno JP. Early developmental elevations of brain kynurenic acid impair cognitive flexibility in adults: reversal with galantamine. Neuroscience. 2013;238:19-28.
102. Alexander KS, Wu HQ, Schwarcz R, Bruno JP. Acute elevations of brain kynurenic acid impair cognitive flexibility: normalization by the alpha7 positive modulator galantamine. Psychopharmacology (Berl). 2012;220:627-637.
103. Pershing ML, Bortz DM, Pocivavsek A, et al. Elevated levels of kynurenic acid during gestation produce neurochemical, morphological, and cognitive deficits in adulthood: implications for schizophrenia. Neuropharmacology. 2015;90:33-41.
104. Olsson SK, Larsson MK, Erhardt S. Subchronic elevation of brain kynurenic acid augments amphetamine-induced locomotor response in mice. J Neural Transm (Vienna). 2012;119:155-163.
105. Potter MC, Elmer GI, Bergeron R, et al. Reduction of endogenous kynurenic acid formation enhances extracellular glutamate, hippocampal plasticity, and cognitive behavior. Neuropsychopharmacology. 2010;35:1734-1742.
106. Kozak R, Campbell BM, Strick CA, et al. Reduction of brain kynurenic acid improves cognitive function. J Neurosci. 2014;34:10592-10602.
107. Nilsson-Todd LK, Nordin C, Jonsson EG, Skogh E, Erhardt S. Cerebrospinal fluid kynurenic acid in Male patients with schizophrenia-correlation with monoamine metabolites. Acta Neuropsychiatr. 2007;19:45-52.
108. Beggiato S, Antonelli T, Tomasini MC, et al. Kynurenic acid, by targeting 7 nicotinic acetylcholine receptors, modulates extracellular GABA levels in the rat striatum in vivo. Eur J Neurosci. 2013;37:1470-1477.
109. Carpenedo R, Pittaluga A, Cozzi A, et al. Presynaptic kynurenate-sensitive receptors inhibit glutamate release. Eur J Neurosci. 2001;13:2141-2147.
110. Konradsson-Geuken A, Wu HQ, Gash CR, et al. Cortical kynurenic acid bi-directionally modulates prefrontal glutamate levels as assessed by microdialysis and rapid electrochemistry. Neuroscience. 2010;169:1848-1859.
111. Konradsson-Geuken A, Gash CR, Alexander K, et al. Second-by-second analysis of alpha 7 nicotine receptor regulation of glutamate release in the prefrontal cortex of awake rats. Synapse. 2009;63:1069-1082.
112. Wu HQ, Pereira EF, Bruno JP, Pellicciari R, Albuquerque EX, Schwarcz R. The astrocyte-derived alpha7 nicotinic receptor antagonist kynurenic acid controls extracellular glutamate levels in the prefrontal cortex. J Mol Neurosci. 2010;40:204-210.
113. Lopes C, Pereira EF, Wu HQ, et al. Competitive antagonism between the nicotinic allosteric potentiating ligand galantamine and kynurenic acid at alpha7 nicotinic receptors. J Pharmacol Exp Ther. 2007;322:48-58.
114. Wu HQ, Rassoulpour A, Schwarcz R. Kynurenic acid leads, dopamine follows: A new case of volume transmission in the brain J Neural Transm (Vienna). 2007;114:33-41.
115. Amori L, Wu HQ, Marinozzi M, Pellicciari R, Guidetti P, Schwarcz R. Specific inhibition of kynurenate synthesis enhances extracellular dopamine levels in the rodent striatum. Neuroscience. 2009;159:196-203.
116. Erhardt S, Engberg G. Increased phasic activity of dopaminergic neurones in the rat ventral tegmental area followingpharmacologically elevated levels of endogenous kynurenic acid. Acta Physiol Scand. 2002;175:45-53.
117. Erhardt S, Oberg H, Mathe JM, Engberg G. Pharmacological elevation of endogenous kynurenic acid levels activates nigral dopamine neurons. Amino Acids. 2001;20:353-362.
118. Linderholm KR, Andersson A, Olsson S, et al. Activation of rat ventral tegmental area dopamine neurons by endogenous kynurenic acid: A pharmacological analysis. Neuropharmacology. 2007;53:918-924.
119. Schwieler L, Erhardt S, Nilsson L, Linderholm K, Engberg G. Effects of COX-1 and COX-2 inhibitors on the firing of rat midbrain dopaminergic neurons-possible involvement of endogenous kynurenic acid. Synapse. 2006;59:290-298.
120. Schwieler L, Linderholm KR, Nilsson-Todd LK, Erhardt S, Engberg G. Clozapine interacts with the glycine site of the NMDA receptor: electrophysiological studies of dopamine neurons in the rat ventral tegmental area. Life Sci. 2008;83:170-175.
121. Liu XC, Holtze M, Powell SB, et al. Behavioral disturbances in adult mice following neonatal virus infection or kynurenine treatment-role of brain kynurenic acid. Brain Behav Immun. 2014;36:80-89.
122. Olsson SK, Andersson AS, Linderholm KR, et al. Elevated levels of kynurenic acid change the dopaminergic response to amphetamine: implications for schizophrenia. Int J Neuropsychopharmacol. 2009;12:501-512.
123. Schwieler L, Erhardt S. Inhibitory action of clozapine on rat ventral tegmental area dopamine neurons following increased levels of endogenous kynurenic acid. Neuropsychopharmacology. 2003;28:1770-1777.
124. Zmarowski A, Wu HQ, Brooks JM, et al. Astrocyte-derived kynurenic acid modulates basal and evoked cortical acetylcholine release. Eur J Neurosci. 2009;29:529-538.
125. Beggiato S, Tanganelli S, Fuxe K, Antonelli T, Schwarcz R, Ferraro L. Endogenous kynurenic acid regulates extracellular GABA levels in the rat prefrontal cortex. Neuropharmacology. 2014;82:11-18.
126. Amori L, Guidetti P, Pellicciari R, Kajii Y, Schwarcz R. On the relationship between the two branches of the kynurenine pathway in the rat brain in vivo. J Neurochem. 2009;109:316-325.
127. Pellicciari R, Rizzo RC, Costantino G, et al. Modulators of the kynurenine pathway of tryptophan metabolism: synthesis and preliminary biological evaluation of (S)-4-(ethylsulfonyl)benzoylalanine, a potent and selective kynurenine aminotransferase II (KAT II) inhibitor. ChemMedChem. 2006;1:528-531.
128. Wu HQ, Okuyama M, Kajii Y, Pocivavsek A, Bruno JP, Schwarcz R. Targeting kynurenine aminotransferase II in psychiatric diseases: promising effects of an orally active enzyme inhibitor. Schizophr Bull. 2014;40(suppl 2):S152-S158.
129. Choi KH, Wykes T, Kurtz MM. Adjunctive pharmacotherapy for cognitive deficits in schizophrenia: meta-analytical investigation of efficacy. Br J Psychiatry. 2013;203:172-178.
130. Conley RR, Boggs DL, Kelly DL, et al. The effects of galantamine on psychopathology in chronic stable schizophrenia. Clin Neuropharmacol. 2009;32:69-74.
131. Lindenmayer JP, Khan A. Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia. Schizophr Res. 2011;125:267-277.
132. Ball HJ, Jusof FF, Bakmiwewa SM, Hunt NH, Yuasa HJ. Tryptophan-catabolizing enzymes-party of three. Front Immunol. 2014;5:485.
133. Fatokun AA, Hunt NH, Ball HJ. Indoleamine 2, 3-dioxygenase 2 (IDO2) and the kynurenine pathway: characteristics and potential roles in health and disease. Amino Acids. 2013;45:1319-1329.
134. Miller CL. The evolution of schizophrenia: A model for selection by infection, with a focus on NAD. Curr Pharm Des. 2009;15:100-109.
135. Yu CP, Pan ZZ, Luo DY. TDO as a therapeutic target in brain diseases. Metab Brain Dis. 2016;31:737-747.
136. Schwieler L, Erhardt S, Erhardt C, Engberg G. Prostaglandinmediated control of rat brain kynurenic acid synthesis-opposite actions by COX-1 and COX-2 isoforms. J Neural Transm (Vienna). 2005;112:863-872.
137. Muller N. Inflammation and the glutamate system in schizophrenia: implications for therapeutic targets and drug development. Expert Opin Ther Targets. 2008;12:1497-1507.
138. Akhondzadeh S, Tabatabaee M, Amini H, Ahmadi Abhari SA, Abbasi SH, Behnam B. Celecoxib as adjunctive therapy in schizophrenia: A double-blind, randomized and placebocontrolled trial. Schizophr Res. 2007;90:179-185.
139. Rappard F, Muller N. Celecoxib add-on therapy does not have beneficial antipsychotic effects over risperidone alone in schizophrenia. Neuropsychopharmacology. 2004;29:S222.
140. Golightly KL, Lloyd JA, Hobson JE, Gallagher P, Mercer G, Young AH. Acute tryptophan depletion in schizophrenia. Psychol Med. 2001;31:75-84.
141. Hitsman B, Spring B, Wolf W, Pingitore R, Crayton JW, Hedeker D. Effects of acute tryptophan depletion on negative symptoms and smoking topography in nicotinedependent schizophrenics and nonpsychiatric controls. Neuropsychopharmacology. 2005;30:640-648.
142. Sharma RP, Shapiro LE, Kamath SK, Soll EA, Watanabe MD, Davis JM. Acute dietary tryptophan depletion: effects on schizophrenic positive and negative symptoms. Neuropsychobiology. 1997;35:5-10.
143. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276.
144. Green MF, Nuechterlein KH, Gold JM, et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia: The NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry. 2004;56:301-307.